Modality
Peptide
MOA
KRASG12Di
Target
IL-17A
Pathway
Notch
SMAWet AMDSLE
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
Dec 2021
→ Aug 2030
Phase 2Current
NCT07211223
1,373 pts·Wet AMD
2021-12→2030-08·Recruiting
1,373 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-244.4y awayPh2 Data· Wet AMD
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2030-08-24 · 4.4y away
Wet AMD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07211223 | Phase 2 | Wet AMD | Recruiting | 1373 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |